Who are Cervarix®, GlaxoSmithKline's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cervarix-glaxosmithkline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Cervarix®, GlaxoSmithKline — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cervarix®, GlaxoSmithKline (Cervarix®, GlaxoSmithKline) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bivalent HPV vaccine. Area: Oncology.

marketed Bivalent HPV vaccine HPV types 16 and 18 L1 capsid protein Oncology Biologic Live · refreshed every 30 min

Target snapshot

Cervarix®, GlaxoSmithKline (Cervarix®, GlaxoSmithKline) — Cancer Prevention and Research Institute, Italy. Cervarix is a bivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 16 and 18, preventing infection and cervical cancer development.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cervarix®, GlaxoSmithKline TARGET	Cervarix®, GlaxoSmithKline	Cancer Prevention and Research Institute, Italy	marketed	Bivalent HPV vaccine	HPV types 16 and 18 L1 capsid protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bivalent HPV vaccine class)

Cancer Prevention and Research Institute, Italy · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cervarix®, GlaxoSmithKline — Competitive Intelligence Brief. https://druglandscape.com/ci/cervarix-glaxosmithkline. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing